MSCI:NYSEMSCI Inc. Analysis
Data as of 2026-03-10 - not real-time
$564.41
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
MSCI Inc. is trading at $564.41, comfortably above its 20‑day SMA of $549.37 but still below the 50‑day SMA of $571.98, indicating a short‑term price edge while medium‑term momentum remains neutral. The RSI sits at 50.9 and the MACD histogram is positive (3.23) with a bullish signal, suggesting limited downside pressure in the near term. The company posted Q4 2025 earnings that beat expectations (EPS $4.66 vs $4.60) and delivered 10.6% revenue growth, with ultra‑high gross (82.4%) and operating margins (55.9%). However, a DCF‑derived fair value of $258.28 and a trailing P/E of 35.97 versus the industry average of 17.38 flag a significant valuation premium. Analysts remain upbeat, issuing a consensus “Buy” with a median target of $700, implying roughly 20% upside relative to current levels. The dividend yield of 1.45% is backed by a 45.9% payout ratio and strong free cash flow, supporting sustainability. Volume has been trending down (current volume 423k vs 10‑day average 663k), but beta of 0.81 points to lower systematic risk. Volatility remains elevated at 43% over the past 30 days, and the max drawdown of –18% underscores the stock’s sensitivity to market swings. Recent strategic moves, notably the Vantager acquisition to broaden data capabilities and the upcoming February 2026 Index Review, reinforce MSCI’s growth narrative. Overall, the blend of solid fundamentals, modest dividend, and analyst optimism is tempered by a high price relative to intrinsic estimates and sector‑wide valuation concerns.
Given these dynamics, MSCI appears positioned for continued earnings expansion but may face valuation correction pressures, making a cautious, growth‑oriented stance prudent.
Given these dynamics, MSCI appears positioned for continued earnings expansion but may face valuation correction pressures, making a cautious, growth‑oriented stance prudent.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD and price above 20‑day SMA
- Earnings beat and strong margin profile
- Analyst consensus buy with near‑term upside potential
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Revenue growth of 10.6% and expanding data‑analytics franchise
- Sustainable dividend payout and robust free cash flow
- Strategic Vantager acquisition enhancing product suite
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Valuation premium relative to DCF and industry peers
- Elevated volatility and potential for price correction
- Continued exposure to regulatory and ESG compliance trends
Key Metrics & Analysis
Financial Health
Revenue Growth10.60%
Profit Margin38.36%
P/E Ratio36.0
ROA19.17%
P/B Ratio-15.6
Op. Cash Flow$1.6B
Free Cash Flow$1.2B
Industry P/E17.4
Technical Analysis
TrendNeutral
RSI50.9
Support$501.08
Resistance$579.07
MA 20$549.37
MA 50$571.98
MA 200$564.55
MACDBullish
VolumeDecreasing
Fear & Greed Index79.88
Valuation
Fair Value$258.28
Target Price$678.31
Upside/Downside20.18%
GradeOvervalued
TypeGrowth
Dividend Yield1.45%
Risk Assessment
Beta0.81
Volatility43.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.